Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ: NBIX )

136.53 -0.46 (-0.34%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
Via Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. 
Via Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing? 
Via Chartmill
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
Exposures Product Safety
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
So Much For Expecting The Fed To Stick The Landing
Now is not the time to be fully invested. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
NASDAQ:NBIX, a growth stock which is not overvalued.
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio?
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. 
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Via Benzinga
Key Takeaways From Neurocrine Biosciences Analyst Ratings
Via Benzinga
Exploring NASDAQ:NBIX's quality characteristics.
Reasonable growth and debt and a high ROIC for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. 
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a quality stock. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals. 
Via Chartmill
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.